Skip to main content

Advertisement

SpringerLink
Log in

Fulminant diabetes induced by PD-1 and PD-L1 inhibitors: what about glucose variability?

  • Short Communication
  • Published:
Acta Diabetologica Aims and scope Submit manuscript

A Letter to the Editor to this article was published on 01 December 2018

The Original Article was published on 25 October 2018

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Tassone F, Colantonio I, Gamarra E et al (2018) Nivolumab-induced fulminant type 1 diabetes (T1D): the first Italian case report with long follow-up and flash glucose monitoring. Acta diabetologica. https://doi.org/10.1007/s00592-018-1246-4 (PubMed PMID: 30361845)

    Article  PubMed  Google Scholar 

  2. Monnier L, Colette C, Wojtusciszyn A et al (2017) Toward defining the threshold between low and high glucose variability in diabetes. Diabetes Care 40(7):832–838 (PubMed PMID: 28039172)

    Article  PubMed  CAS  Google Scholar 

  3. Marchand L, Reffet S, Vouillarmet J, Cugnet-Anceau C, Disse E, Thivolet C (2018) The 36% coefficient of variation for glucose proposed for separating stable and labile diabetes is clinically relevant: a continuous glucose monitoring-based study in a large population of type 1 diabetes patients. Diabetes Metab. https://doi.org/10.1016/j.diabet.2018.05.009 (PubMed PMID: 29910090)

    Article  PubMed  Google Scholar 

  4. Marchand L, Thivolet A, Dalle S et al (2018) Diabetes mellitus induced by PD-1 and PD-L1 inhibitors: description of pancreatic endocrine and exocrine phenotype. Acta Diabetol. https://doi.org/10.1007/s00592-018-1234-8 (PubMed PMID: 30284618)

    Article  PubMed  Google Scholar 

  5. Marchand L, Paulus V, Fabien N et al (2017) Nivolumab-induced acute diabetes mellitus and hypophysitis in a patient with advanced pulmonary pleomorphic carcinoma with a prolonged tumor response. J Thorac Oncol. 12(11):e182–e184 (PubMed PMID: 29074210)

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Endocrinology and Diabetes, Hospices Civils de Lyon, Lyon-Sud Hospital, 165 chemin du Grand Revoyet, 69310, Pierre-Bénite, France

    Lucien Marchand, Sophie Reffet, Emmanuel Disse, Julien Vouillarmet, Christine Cugnet-Anceau & Charles Thivolet

  2. Department of Dermatology, Hospices Civils de Lyon, Lyon-Sud Hospital, Pierre-Bénite, France

    Stéphane Dalle

  3. ImmuCare (Immunology Cancer Research), Hospices Civils de Lyon, Lyon, France

    Stéphane Dalle & Christine Cugnet-Anceau

  4. Lyon 1 University, CarMeN Laboratory (INSERM U1060, INRA U1235, Université Claude Bernard Lyon1, INSA-Lyon), Oullins, France

    Emmanuel Disse & Charles Thivolet

Authors
  1. Lucien Marchand
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sophie Reffet
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Stéphane Dalle
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Emmanuel Disse
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Julien Vouillarmet
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Christine Cugnet-Anceau
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Charles Thivolet
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lucien Marchand.

Ethics declarations

Conflict of interest

The authors declare that there is no conflict of interest associated with this manuscript.

Human and animal rights

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008.

Informed consent

Informed consent was obtained from all patients for being included in the study.

Additional information

Managed by Massimo Porta.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Marchand, L., Reffet, S., Dalle, S. et al. Fulminant diabetes induced by PD-1 and PD-L1 inhibitors: what about glucose variability?. Acta Diabetol 56, 377–378 (2019). https://doi.org/10.1007/s00592-018-1262-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00592-018-1262-4

Keywords

Search

Navigation